Eli Lilly and Company executive vice-president and Lilly International president Ilya Yuffa stated: "It is exciting to see Kisunla's marketing authorisation in Australia, marking it as the 13th ...

"Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly has spent recent years reintroducing itself to the public via a series of corporate campaigns, and its latest push goes a step further.

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible ...

Notably, Eli Lilly's CEO attributes 45% of the Company's year-over-year revenue growth to strong sales of Zepbound and Mounjaro.

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling.